Antipsychotic medications are the most common cause of tardive dyskinesia (TD), but they’re not the only ones. Anti-nausea drugs, certain antidepressants, and even mood stabilizers like lithium have been linked to these involuntary movements. The risk varies widely depending on the specific drug, how long you take it, and your personal risk factors.
First-Generation Antipsychotics: The Highest Risk
Older antipsychotics, sometimes called “typical” antipsychotics, carry the greatest risk of TD. These include haloperidol, chlorpromazine, and perphenazine. In clinical trials, about 6.5% of people taking these drugs developed TD per year of use. That annual rate might sound modest, but it compounds over time. Among people taking older antipsychotics for five years, roughly 32% developed TD. After 15 years, the estimate climbed to 57%, and after 25 years, to 68%.
These drugs work by blocking dopamine receptors in the brain. Over time, those receptors can become hypersensitive to compensate for the blockade. The increased dopamine activity also generates oxygen radicals that damage neurons in the striatum, a brain region critical for controlling movement. That damage accumulates gradually until involuntary movements emerge.
Second-Generation Antipsychotics: Lower but Real Risk
Newer “atypical” antipsychotics cut the risk roughly in half compared to older ones, with an annual incidence of about 2.6%. That’s a meaningful reduction, but TD still occurs. Published reports have found point prevalence rates around 13% among people on second-generation antipsychotics, compared to about 32% for first-generation drugs.
Not all newer antipsychotics carry the same level of risk. A meta-analysis in World Psychiatry found that aripiprazole had the strongest advantage over older drugs, while quetiapine showed the smallest benefit. Olanzapine stood out within the newer class itself, with about a 33% lower risk of TD compared to other non-clozapine second-generation options. Risperidone and paliperidone showed no significant difference from other newer antipsychotics.
The full list of second-generation antipsychotics studied includes aripiprazole, asenapine, clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone, lurasidone, cariprazine, brexpiprazole, and several others. If you’re taking any of these, TD is possible, even if the odds are lower than with older drugs.
Metoclopramide and Anti-Nausea Drugs
This is the category that catches many people off guard. Metoclopramide (brand name Reglan) is prescribed for acid reflux and nausea, and it works on the same dopamine pathways that antipsychotics target. The FDA label carries a black box warning: treatment beyond 12 weeks should be avoided except in rare cases, because both the risk of developing TD and the likelihood it becomes permanent increase with longer use and higher cumulative doses. Despite that warning, about 20% of patients prescribed metoclopramide take it for longer than 12 weeks.
Prochlorperazine, commonly used for nausea and migraines, belongs to the same drug family as older antipsychotics and carries a similar mechanism of risk. If you’ve been prescribed any anti-nausea medication long-term, it’s worth knowing whether it acts on dopamine.
Antidepressants and Mood Stabilizers
TD from antidepressants is far less common than from antipsychotics, but it’s documented. When it does occur, it appears more often in adults over 65, likely because aging brains are more vulnerable to the dopamine-related changes that drive TD.
Lithium, a mood stabilizer widely used for bipolar disorder, has also been linked to TD. Case reports describe patients developing involuntary movements after years of lithium use alone, without any antipsychotic exposure. One reported case involved a 68-year-old woman who developed TD after 15 years on a low dose. Another involved a 67-year-old woman on lithium for 10 years. In at least one case, the movements improved when the dose was reduced, suggesting lithium-induced TD may be reversible if caught early.
Who Is Most at Risk
The medication matters, but so does who’s taking it. Your risk of TD increases after age 40, and adults over 65 face the highest risk, likely because of age-related changes in the brain’s dopamine system. One study found that postmenopausal women developed TD at rates as high as 30% after about a year on antipsychotic medications. Women in general have a slightly higher risk than men.
Race plays a role as well. Studies show that Black Americans develop TD more often than white Americans, while people of Filipino and Asian descent appear to have a lower risk. Having bipolar disorder also increases your odds compared to others taking the same medications. For metoclopramide specifically, the identified risk factors are being 65 or older, being female, having diabetes, and taking the drug for 12 or more weeks.
What TD Movements Look Like
TD most commonly affects the face and mouth. You might notice lip smacking, puckering, or pouting. Jaw movements like chewing, clenching, or lateral shifting are common. The tongue may dart in and out of the mouth involuntarily. Facial muscles can produce frowning, rapid blinking, or grimacing.
Movements can also affect the arms and legs, appearing as irregular, purposeless motions of the fingers, wrists, toes, or feet. These differ from tremors because they’re not rhythmic or repetitive. They look more random and flowing. The trunk can be involved too, with rocking, twisting, or squirming of the neck, shoulders, and hips. Clinicians track these movements across seven body areas using a standardized scale that rates severity from 0 (none) to 4 (severe).
How Quickly TD Can Develop
TD typically requires at least a few months of medication exposure to develop, though older adults can develop it sooner. The movements often appear while someone is still taking the medication, but they can also emerge after the dose is reduced or the drug is stopped entirely. This makes TD tricky to spot early, because the timing doesn’t always line up with what you’d expect.
TD can be irreversible and lifelong, which is why early recognition matters. Stopping the offending drug as soon as possible offers the best chance of recovery, though that decision always involves weighing the movement disorder against the condition being treated.
FDA-Approved Treatments for TD
Two medications are specifically approved to treat TD. Both work by reducing the amount of dopamine available in nerve terminals, calming the overactive signaling that drives the involuntary movements. Valbenazine is taken once daily and typically started at a lower dose before increasing after one week. Deutetrabenazine is taken twice daily and adjusted weekly based on how well it’s working and how well it’s tolerated. These are the first drugs developed specifically for TD and represent a significant shift from earlier approaches, which mostly involved switching antipsychotics or hoping the movements would resolve on their own.